➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
Medtronic
Moodys
McKesson

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

TRIFERIC AVNU Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Triferic Avnu patents expire, and what generic alternatives are available?

Triferic Avnu is a drug marketed by Rockwell Medical Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.

US ANDA Litigation and Generic Entry Outlook for Triferic Avnu

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 17, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for TRIFERIC AVNU
International Patents:12
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 10
Formulation / Manufacturing:see details
DailyMed Link:TRIFERIC AVNU at DailyMed
Drug patent expirations by year for TRIFERIC AVNU
Generic Entry Opportunity Date for TRIFERIC AVNU
Generic Entry Date for TRIFERIC AVNU*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIFERIC AVNU

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rockwell Medical Technologies, Inc.Phase 3
Rockwell Medical Technologies, Inc.Phase 2
Rockwell Medical Technologies, Inc.Phase 1/Phase 2

See all TRIFERIC AVNU clinical trials

Pharmacology for TRIFERIC AVNU

US Patents and Regulatory Information for TRIFERIC AVNU

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rockwell Medical Inc TRIFERIC AVNU ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 212860-001 Mar 27, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Boehringer Ingelheim
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.